Rakesh Dhanya

Rakesh Dhanya

Auto-generated profile, based on publicly available information

Rakesh Dhanya

Sankalp India Foundation, Bangalore, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2020
Verified
Journal Article
Closed access
RDRakesh Dhanya
Rakesh Dhanya
ASAmit Sedai
Amit Sedai
KAKumari Ankita
Kumari Ankita
LPLalith Parmar
Lalith Parmar
RARajat Kumar Agarwal
Rajat Kumar Agarwal
Lawrence FaulknerLawrence Faulkner
Lawrence Faulkner

1 September 2017 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
RARajat Kumar Agarwal
Rajat Kumar Agarwal
AKAnkita Kumari
Ankita Kumari
ASAmit Sedai
Amit Sedai
LPLalith Parmar
Lalith Parmar
RDRakesh Dhanya
Rakesh Dhanya
LFLawrence Faulkner
Lawrence Faulkner
Three-loci low-resolution (LR) or intermediate-resolution HLA typing is generally considered adequate in the related blood and marrow transplantation (BMT) context. However, a single high-resolution (HR) mismatch may have a similar adverse impact on BMT outcome as an LR one. We sought to determine the frequency of mismatches that may go undetected when standard typing (LR or 3-loci HR) is used compared with 6-loci HR typing for related donor compatibility testing, and to assess its impact on relevant BMT outcomes. We analyzed data from a total of 2554 6-loci (HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1) HR sequence-based typing (full typing [FT]) from 754 patients, 1011 siblings, and 789 parents done at DKMS Germany (www.DKMS.de) between January 1, 2014, and June 21, 2016. We also studied 38 cases in which the family had undergone 3-loci HLA typing (standard typing [ST]). Patients were from India (70%), Pakistan (22%), and Sri Lanka (8%). The IMGT/HLA database (www.ebi.ac.uk/ipd/imgt/hla) was used to tease out nonpermissive DPB1 mismatches. HLA disparity-related outcomes, such as rejection and graft-versus-host disease (GVHD) were assessed in a retrospective matched-pair cohort of 50 patients (25 with ST and 25 with FT) who underwent BMT for severe thalassemia from compatible related donors. We found fully matched (either 12/12 HR matches or with a single permissive DPB1 mismatch) related donors for 285 patients (38%). Of these donors, 89% were siblings and 11% were parents. The likelihood of matching on an individual locus on LR but not on HR was found to be 5%. A total of 9 donors (3%; 7 siblings and 2 parents) who would have been considered a full match by HR typing on A, B, and DRB1 alone were not a match by extended 6-loci HR typing. Five of these 9 donors had a mismatch on C or DQB1, and 4 had a nonpermissive DPB1 mismatch. In this group, 5 donors (56%) belonged to a consanguineous family, in 2 donors (22%) there was no reported consanguinity, and in 2 donors (22%) consanguinity was unknown. We identified 18 donors (6%; 13 siblings and 5 parents) who would have been considered a 12/12 match by LR HLA typing alone but were found not to match on extended HR typing. In this group, 11 donors (61%) were from consanguineous families, 3 donors (17%) had no reported consanguinity, and in 4 donors (22%) consanguinity was unknown. Outcome analysis showed that the actuarial proportion of patients with GVHD was 4% in the FT group compared with 16% in the ST group, with log-rank P = .1952. The ST group included 2 patients with grade III-IV acute GVHD and 1 patient each with moderate and severe chronic GVHD, whereas the FT group only 1 patient with grade III acute GVHD. We conclude that even in the context of related donors, the use of LR and/or 3-loci (A, B, and DRB1) HR HLA typing might result in a sizable risk of missing a clinically relevant mismatch, which may have an adverse impact on transplantation outcomes. In the Indian subcontinent, this observation is not limited to putatively compatible parents or consanguineous families; we recommend full 6-loci HR HLA typing even for matched related BMTs.

1 December 2017 in Pediatric Hematology Oncology Journal
Verified
Journal Article
Open access
SRStalin Ramprakash
Stalin Ramprakash
RARajat Agarwal
Rajat Agarwal
RDRakesh Dhanya
Rakesh Dhanya
PMPriya Marwah
Priya Marwah
RSRajpreet Soni
Rajpreet Soni
LFLawrence Faulkner
Lawrence Faulkner

1 March 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
RDRakesh Dhanya
Rakesh Dhanya
RARajat Kumar Agarwal
Rajat Kumar Agarwal
SRStalin Ramprakash
Stalin Ramprakash
DTDeepa Trivedi
Deepa Trivedi
VSVaibhav Shah
Vaibhav Shah
Lawrence FaulknerLawrence Faulkner
Lawrence Faulkner
The utility of weekly rectal swab surveillance cultures (RSSCs) as a resource to identify gut colonization with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae carbapenemase (KPC)-producing organisms and guide empirical antibiotic therapy in hematopoietic stem cell transplantation (HSCT) recipients continues to be a subject of interest. There is an urgent need to assess and justify modifications to empirical antibiotics based on regional epidemiology and patient groups. This study aimed to study the utility of weekly rectal swab surveillance cultures (RSSCs) to guide empirical antibiotic therapy and to examine the impact of gut colonization on transplantation outcomes. This retrospective analysis of 317 successive first HSCTs performed mainly for hemoglobinopathies was conducted in 3 pediatric bone marrow transplantation centers in the Indian subcontinent between April 2016 and April 2021. Transplantation, infection control, and febrile neutropenia management protocols were identical in the 3 centers. First-line antibiotics were chosen based on RCCS reports, with meropenem used for ESBL and high-dose meropenem with colistin used for carbapenemase-resistant colonization for first half of the study, with no adjustment made in the second half. Clinical response to antibiotics, long-term outcomes, antibiotic-resistant bacteremia, and acute graft-versus-host disease (GVHD) were analyzed. The log-rank test, chi-square, and Wilcoxon rank-sum tests were used to compare data using R Statistical software. Of the 871 weekly RSSCs done, 162 were positive for ESBL- or KPC-resistant organism. RCCSs were ESBL-positive in 106 patients (33%) and KPC-positive in 10 patients (3%). Among the 97 ESBL-positive patients for whom a antimicrobial susceptibility testing report was available, only 22 (25%) demonstrated clinical resistance to piperacillin-tazobactam (Pip-Taz). Among the 10 KPC-positive patients, only 4 (40%) demonstrated clinical resistance to Pip-Taz and 3 (30%) had clinical resistance to meropenem. Two-thirds of patients with ESBL-positive RSSC in whom first-line empirical antibiotics were used responded clinically. Even among the 15 patients who were resistant to first-line empirical antibiotics (Pip-Taz) on RSSC reports, 67% responded clinically to Pip-Taz. Twenty-seven of these patients (56%) never needed carbapenem therapy. Empirical Pip-Taz therapy in ESBL-positive patients did not prolong meropenem use within 100 days of transplantation (P = .18). All patients with a KPC-positive RSSC who received first-line empirical antibiotics responded clinically, including 4 who were resistant to Pip-Taz and 3 who were meropenem-resistant on RCCS. Comparing patients who were ESBL-positive, KPC-positive, and not positive for either showed no statistically significant differences in overall survival (OS) (P = .95), disease-free survival (DFS) (P = .45), transplantation-related mortality (TRM) (P = .97), graft rejection (P = .68), or rate of acute GVHD grade II-IV (P = .78). No statistically significant differences were seen between the ESBL-positive patients who received and those who did not receive higher-level empirical antibiotics in OS (P = .32), DFS (P = .64), TRM (P = .65), graft rejection (P = .46), acute GVHD grade II-IV (P = .26), or antibiotic-resistant bacteremia (P = .3). In the context of HSCT for nonmalignant hematologic disorders, choosing empiric antibiotic therapy based on RSSCs is not justified, even in regions with a high prevalence of antimicrobial resistance. Antimicrobial susceptibility testing reports in surveillance cultures did not correlate with in vivo clinical response. Colonization reported on weekly RSSCs showed no correlation with clinical outcomes. © 2021 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

23 January 2019 in JMIR Medical Informatics
Verified
Journal Article
Open access
RARajat Kumar Agarwal
Rajat Kumar Agarwal
ASAmit Sedai
Amit Sedai
KAKumari Ankita
Kumari Ankita
LPLalith Parmar
Lalith Parmar
RDRakesh Dhanya
Rakesh Dhanya
Lawrence FaulknerLawrence Faulkner
Lawrence Faulkner
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Successful models of information and communication technology (ICT) applied to cost-effective delivery of quality care in low- and middle-income countries (LMIC) are an increasing necessity. Severe thalassemia (ST) is one of the most common life-threatening non-communicable diseases of children globally. Objective: To study the impact of ICT on quality of care for ST patients in LMIC. Methods: A total of 1110 patients with ST from 5 centers in India were followed over a one-year period. The impact of consistent use of a web-based application platform designed to assist comprehensive management of ST (ThalcareTM) on key indicators of quality of care such as minimum (pre-transfusion) hemoglobin, serum ferritin, liver size and spleen size was assessed. Results: For four centers, the improvement in mean pre-transfusion hemoglobin level was statistically very significant (P<0.001). Four out of five centers achieved reduction in mean ferritin levels with two displaying a highly significant drop in ferritin (P=0.003 and P=0.0002). One of the five centers did not record liver and spleen size on palpation, but out of the remaining 4 centers, 2 witnessed a strongly significant drop in liver and spleen size (P <0.01), 1 witnessed moderate drop (P= 0.05 for liver P =0.03 for spleen size) while the fourth witnessed a moderately increase in liver size (P =0.08) and insignificant change in spleen size (P=0.12). Conclusions: Implementation of Computer-Assisted Treatment Planning and Performance Assessment positively impacted on indices reflecting effective delivery of care to patients suffering from ST in LMIC consistently.

1 December 2017 in Pediatric Hematology Oncology Journal
Verified
Journal Article
Open access
RARajat Kumar Agarwal
Rajat Kumar Agarwal
ASAmit Sedai
Amit Sedai
KAKumari Ankita
Kumari Ankita
LPLalith Parmar
Lalith Parmar
RDRakesh Dhanya
Rakesh Dhanya
LFLawrence Faulkner
Lawrence Faulkner